These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 22644796

  • 1. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
    Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO.
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
    [Abstract] [Full Text] [Related]

  • 2. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T, Sasajima T, Doi Y, Oka S, Ono M, Kanagawa M, Baden A, Mizoi K, Shimizu H.
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
    Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O.
    Ann Oncol; 2014 Jul; 25(7):1442-1447. PubMed ID: 24723487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    Lu G, Zhu P, Rao M, Linendoll N, Buja LM, Bhattacharjee MB, Brown RE, Ballester LY, Tian X, Pilichowska M, Wu JK, Hergenroeder GW, Glass WF, Chen L, Zhang R, Pillai AK, Hunter RL, Zhu JJ.
    J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
    [Abstract] [Full Text] [Related]

  • 10. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C.
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [Abstract] [Full Text] [Related]

  • 11. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
    Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK, Weyerbrock A.
    Int J Cancer; 2012 Mar 01; 130(5):1184-94. PubMed ID: 21455987
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K.
    J Neurooncol; 2020 Feb 01; 146(3):451-458. PubMed ID: 32020475
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, Narita Y.
    Radiat Oncol; 2019 Nov 12; 14(1):200. PubMed ID: 31718669
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.